Home » Topics » Regulatory » EMA

EMA
RSS

Amsterdam Molecular Therapeutics provides update on Glybera MAA

Aug. 23, 2010

EMA accepts Optimer Pharma's fidaxomicin MAA for review

Aug. 20, 2010

European Commission grants midostaurin orphan drug status in mastocytosis

Aug. 18, 2010

European Commission grants orphan designation to Vertex's cystic fibrosis candidate

Aug. 18, 2010

EMA validates CTI's expanded pediatric program for pixantrone in NHL

Aug. 16, 2010

Dexamethasone intravitreal implant receives E.U. orphan drug status for noninfectious uveitis

Aug. 16, 2010

MK-4827 receives E.U. orphan drug status in ovarian cancer

Aug. 16, 2010

European Commission grants orphan status to bosutinib in CML

Aug. 13, 2010

Tranilast obtains orphan drug status for prevention of scarring in glaucoma surgery

Aug. 10, 2010

HBGF-1-coated biodegradable device receives E.U. orphan drug status for spinal cord injury

Aug. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...